Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
The revised figure for the US second-quarter GDP price index was 6.4%, compared to a forecast of 6.20% and a previous reading of 6.20%.
2026-08-26
The revised figure for the US second-quarter GDP price index was 6.4%, compared to a forecast of 6.20% and a previous reading of 6.20%.
Back
Other News
2026-08-26
Market news: CME Group will launch wind energy futures and options in the fourth quarter.
Market news: CME Group will launch wind energy futures and options in the fourth quarter.
2026-08-27
People familiar with the matter said the White House plans to announce on Monday a new round of most-favored-nation (MFN) drug-pricing agreements with several mid-sized biotech firms. Under the deals, companies would provide outpatient drug discounts
People familiar with the matter said the White House plans to announce on Monday a new round of most-favored-nation (MFN) drug-pricing agreements with several mid-sized biotech firms. Under the deals, companies would provide outpatient drug discounts to Medicaid so state-paid prices align with their overseas prices; states may opt in. In return, firms would be exempt from a Medicare pilot requiring similar discounts, and some talks include tariff relief. It is unclear which companies are involved or the likely savings. The administration has already reached similar agreements with 17 large drugmakers, including Pfizer and Eli Lilly. Researchers estimate that if the Medicaid pricing mechanism covered 82 high-priced branded drugs, states could save more than $8 billion a year.
Chat with us
, powered by
LiveChat